Last summer, Celltrion revealed that its approved biosimilar to Humira had been added to the Costco Member Prescription Program—a drug discount card program that helps eligible Costco members ...

It will soon be followed onto the market by Stelara competitors from partners Teva and Alvotech, Fresenius Kabi and Accord BioPharma, as well as Celltrion ... about the Humira erosion curve ...

Celltrion was next to announce the availability ... Indications for which Humira’s regulatory exclusivity have already lapsed include rheumatoid arthritis, Crohn’s disease, plaque psoriasis ...

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, and the FDA approval of the third tocilizumab biosimilar.

“It’s a matter of how, for whom, and at what price?” Read more from Jonathan. Peak U.S. sales of Humira, made by pharmaceutical giant AbbVie, were $18.6 billion in 2022. Then, in ...

Celltrion announced on the 23rd that it has completed the launch of 'Steqeyma' (ingredient name ustekinumab), a biosimilar for the treatment of autoimmune diseases, in five European countries ...

(MENAFN- IANS) Seoul, Jan 31 (IANS) Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US ...

Celltrion is aggressively pursuing global clinical trials for a new antibody-drug conjugate (ADC) cancer treatment. Celltrion submitted an investigational new drug (IND) application to the U.S ...